JP2019523772A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523772A5
JP2019523772A5 JP2018565715A JP2018565715A JP2019523772A5 JP 2019523772 A5 JP2019523772 A5 JP 2019523772A5 JP 2018565715 A JP2018565715 A JP 2018565715A JP 2018565715 A JP2018565715 A JP 2018565715A JP 2019523772 A5 JP2019523772 A5 JP 2019523772A5
Authority
JP
Japan
Prior art keywords
group
compound
formula
amino
protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523772A (ja
JP6998896B2 (ja
Filing date
Publication date
Priority claimed from CN201610432126.5A external-priority patent/CN107513069A/zh
Application filed filed Critical
Publication of JP2019523772A publication Critical patent/JP2019523772A/ja
Publication of JP2019523772A5 publication Critical patent/JP2019523772A5/ja
Application granted granted Critical
Publication of JP6998896B2 publication Critical patent/JP6998896B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565715A 2016-06-16 2017-06-15 キラルピロロピリミジン化合物の製造方法 Active JP6998896B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610432126.5 2016-06-16
CN201610432126.5A CN107513069A (zh) 2016-06-16 2016-06-16 手性吡咯并嘧啶化合物的制备方法
PCT/CN2017/088421 WO2017215627A1 (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法

Publications (3)

Publication Number Publication Date
JP2019523772A JP2019523772A (ja) 2019-08-29
JP2019523772A5 true JP2019523772A5 (enExample) 2020-05-21
JP6998896B2 JP6998896B2 (ja) 2022-02-04

Family

ID=60663390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565715A Active JP6998896B2 (ja) 2016-06-16 2017-06-15 キラルピロロピリミジン化合物の製造方法

Country Status (6)

Country Link
US (1) US10766901B2 (enExample)
EP (1) EP3473625B1 (enExample)
JP (1) JP6998896B2 (enExample)
CN (3) CN107513069A (enExample)
ES (1) ES2877678T3 (enExample)
WO (1) WO2017215627A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072002A1 (en) * 2018-12-24 2022-03-10 Chia Tai Tianqing Pharmaceuticalgroup Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
CN120267676A (zh) 2020-03-09 2025-07-08 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途
CR20230129A (es) 2020-08-18 2023-07-13 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
WO2022040172A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
CN114085224A (zh) * 2020-08-25 2022-02-25 北京普祺医药科技有限公司 一种吡咯并嘧啶化合物的制备方法
WO2022268083A1 (zh) 2021-06-21 2022-12-29 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物及其药物组合物治疗慢性移植物抗宿主病的用途
CA3226714A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
EP4483883A4 (en) 2022-03-21 2026-03-04 Chia Tai Tianqing Pharmaceutical Group Co Ltd USE OF A PYRROLOPYRIMIDINE COMPOUND IN THE TREATMENT OF MEDIUM-RISK OR HIGH-RISK MYELOFIBROSSE
WO2024027790A1 (zh) 2022-08-04 2024-02-08 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗急性移植物抗宿主病的用途
AU2023331168A1 (en) * 2022-08-22 2024-08-29 Granules India Limited An improved process for the preparation of ruxolitinib
CN120882718A (zh) * 2023-03-17 2025-10-31 北京普祺医药科技股份有限公司 吡咯并嘧啶化合物或其可药用盐的制备方法
WO2024230727A1 (zh) * 2023-05-09 2024-11-14 正大天晴药业集团股份有限公司 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5616499A (en) * 1979-07-19 1981-02-17 Yamasa Shoyu Co Ltd 6-c-purine nucleoside derivative and its preparation
JPS5841897A (ja) * 1981-09-04 1983-03-11 Yamasa Shoyu Co Ltd ６−（４−ピラゾリル）プリンリボヌクレオシド誘導体およびその製造法
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
CN103214484B (zh) * 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
PE20211639A1 (es) * 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN103739607A (zh) * 2014-01-22 2014-04-23 无锡方圆环球显示技术股份有限公司 一种基于三并咔唑多臂结构红光材料及其制备方法与应用
WO2015187470A1 (en) * 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CN105218548A (zh) 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
CN105315286B (zh) * 2014-07-30 2018-08-17 连云港润众制药有限公司 西格列汀的制备
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶

Similar Documents

Publication Publication Date Title
JP2022043078A5 (enExample)
JP2019104748A5 (enExample)
JP2007523139A5 (enExample)
JP2018529687A5 (enExample)
JP2015509939A5 (enExample)
JP2008523069A5 (enExample)
JP2012508235A5 (enExample)
JP2018522012A5 (enExample)
RU2011131067A (ru) Стабильные инсектицидные композиции и способы их получения
JP2009533369A5 (enExample)
JP2005053931A5 (enExample)
RU2016133187A (ru) Способ получения n-[(3-аминооксетан-3-ил)метил]-2-(1,1-диоксо-3,5-дигидро-1,4-бензотиазепин-4ил)-6-метил-хиназолин-4-амина
JP2010501516A5 (enExample)
JP2006502283A5 (enExample)
JP2011524871A5 (enExample)
CN1216049C (zh) 西酞普兰的制备方法
JP2017052761A5 (enExample)
JP2016188255A5 (enExample)
RU2015134407A (ru) Способ получения вортиоксетина
RU2016125459A (ru) Способ получения хиральных 2-арилморфолинов
JP2024545294A5 (enExample)
JP2018502174A5 (enExample)
CN101857559B (zh) 手性α-(三氯甲基)胺类化合物及其制备方法
JP2015531767A5 (enExample)
JP2018529703A5 (enExample)